-
Analysis: In Vaccine Race, Middle Income Nations Are At A Disadvantage. Just Ask Peru.
Peru is classified by the World Bank as "upper middle-income." So it has some money to spend on vaccines but not nearly the financial resources of the U.S., the European Union or even wealthier neighbors like Brazil or Chile.
- Categories
- Coronavirus, Health Care
- Region
- Latin America
-
South African Firm to Help Develop COVID-19 Vaccines for the Rest of Africa
The Biovac Institute, a South African vaccine company, is formulating expansion plans aimed at helping Africa become more self-sufficient when its comes to accessing the immunising shots.
- Categories
- Coronavirus
- Region
- Sub-Saharan Africa
-
Addressing COVID-19 While Building Long-Term Capacity: Trends and Opportunities in Africa’s Growing Pharmaceutical Markets
The African pharmaceutical market’s estimated worth is between US $40 – $65 billion, but it remains largely untapped, with a heavy reliance on imports. According to Biodun Awosusi at Health Systems and Development Enterprise, the COVID-19 crisis shows the urgent need to unlock new partnerships and investments to accelerate the local production of medical supplies, medicines and vaccines, which could save lives and create jobs. He explores how Africa’s pharmaceutical sector is responding to the pandemic, and how it could be strengthened for the longer term.
- Categories
- Coronavirus, Health Care
-
Report Spotlights Drug Firms’ Supply Chain Initiatives, Hurdles in LMICs
The almost yearly Access to Medicine Index measures the 20 behemoths of the pharmaceutical industry, encapsulating 70% of global pharmaceutical revenues. However, the report doesn't look at the bottom line: It looks at medicine accessibility in low- and middle-income companies (LMICs), and—as with everything in the past year—COVID-19 made its mark, demanding supply chain innovation and collaboration in new ways.
- Categories
- Coronavirus
-
Global COVID-19 Impact on Vaccines & Drugs Market Growth Is Mainly Attributed Due to Growing Number of People Infected With COVID-19 and Rising Funding for Vaccine Development – PMI
Technological advancements in the pharmaceutical sector comprising the development of nucleic acid vaccines that are DNA- and RNA-based, and which allow the human body to produce vaccine antigen. Such initiatives and activities are expected to support market growth to a substantial extent.
- Categories
- Coronavirus, Technology
-
Report: Countries, Companies Risk Billions in Race for Coronavirus Vaccine
“The crisis in the world is so big that each of us will have to take maximum risk now to put this disease to a stop,” said Paul Stoffels, chief scientific officer at Johnson & Johnson, which has partnered with the U.S. government on a $1 billion investment to speed development and production of its still-unproven vaccine. “If it fails,” Stoffels told Reuters, “it will be bad.”
- Categories
- Coronavirus, Health Care
- Region
- North America
-
Big Pharma’s Blindspot: Before COVID-19, Vaccine and Antiviral Research Went Neglected
Public health experts have warned for years that the world is at risk of a major pandemic, and advocates say Big Pharma showed little interest in developing vaccines — or even antibiotic and antiviral medications — until the latest outbreak offered an opportunity to rake in public funding and turn out massive profits with minimal risk.
- Categories
- Coronavirus, Health Care
Parent Organization
